Coherus BioSciences (CHRS) Receiving Somewhat Positive Press Coverage, Accern Reports

Media coverage about Coherus BioSciences (NASDAQ:CHRS) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Coherus BioSciences earned a news impact score of 0.05 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.2243823675275 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Coherus BioSciences (NASDAQ:CHRS) traded down $1.10 during trading on Friday, reaching $8.35. 1,250,691 shares of the company’s stock were exchanged, compared to its average volume of 604,045. Coherus BioSciences has a 1-year low of $8.10 and a 1-year high of $29.59. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.26). Coherus BioSciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. research analysts expect that Coherus BioSciences will post -4.39 earnings per share for the current fiscal year.

Several equities analysts recently commented on CHRS shares. BidaskClub lowered shares of Coherus BioSciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Zacks Investment Research raised shares of Coherus BioSciences from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Tuesday, August 15th. ValuEngine raised shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $25.00 target price (down previously from $32.00) on shares of Coherus BioSciences in a report on Tuesday, August 8th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $17.00 target price (down previously from $24.00) on shares of Coherus BioSciences in a report on Wednesday, September 27th. Three analysts have rated the stock with a sell rating and nine have assigned a buy rating to the stock. Coherus BioSciences has an average rating of “Buy” and a consensus price target of $31.00.

COPYRIGHT VIOLATION WARNING: “Coherus BioSciences (CHRS) Receiving Somewhat Positive Press Coverage, Accern Reports” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/18/coherus-biosciences-chrs-receiving-somewhat-positive-press-coverage-accern-reports.html.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply